These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

379 related items for PubMed ID: 8761616

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Selegeline may be toxic in presence of increased dopamine concentrations.
    Yu PH, Lai CT, Boulton AA.
    BMJ; 1996 Mar 16; 312(7032):703-4; author reply 704-5. PubMed ID: 8597749
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. [Drug therapy of Parkinson's disease].
    Myllylä V.
    Duodecim; 1997 Mar 16; 113(18):1827-34. PubMed ID: 10892076
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Levodopa in the treatment of Parkinson's disease: current controversies.
    Gerlach M, Reichmann H, Riederer P.
    Mov Disord; 2005 May 16; 20(5):643; author reply 643-4. PubMed ID: 15732130
    [No Abstract] [Full Text] [Related]

  • 33. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Stopping selegeline may lead to problems for patients.
    Anderson KE, Girdwood AC, Wilson JA.
    BMJ; 1996 Mar 16; 312(7032):702; author reply 704-5. PubMed ID: 8597745
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study.
    Van Gerpen JA, Ahlskog JE.
    Neurology; 2001 Jul 24; 57(2):368-9; author reply 369-70. PubMed ID: 11468339
    [No Abstract] [Full Text] [Related]

  • 36. Selegiline as the primary treatment of Parkinson's disease--a long-term double-blind study.
    Myllylä VV, Sotaniemi KA, Hakulinen P, Mäki-Ikola O, Heinonen EH.
    Acta Neurol Scand; 1997 Apr 24; 95(4):211-8. PubMed ID: 9150811
    [Abstract] [Full Text] [Related]

  • 37. [Biochemical basis for using selective monoamine oxidase inhibitors in the treatment of Parkinson's disease. Critical contribution].
    Amato L, Nava L, Rizzo M, Piccoli F.
    Riv Neurol; 1985 Apr 24; 55(1):46-52. PubMed ID: 3927468
    [No Abstract] [Full Text] [Related]

  • 38. Current status of selegiline as a neuroprotective agent in Parkinson's disease.
    Olanow CW, Mytilineou C, Tatton W.
    Mov Disord; 1998 Apr 24; 13 Suppl 1():55-8. PubMed ID: 9613720
    [No Abstract] [Full Text] [Related]

  • 39. Update on antiparkinsonian agents.
    Weiner M.
    Geriatrics; 1982 Sep 24; 37(9):81-4, 89-91. PubMed ID: 6125455
    [No Abstract] [Full Text] [Related]

  • 40. Monoamine oxidase inhibitors--is it time to up the TEMPO?
    Rascol O.
    Lancet Neurol; 2003 Mar 24; 2(3):142-3. PubMed ID: 12849233
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.